Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors in the central anxious technique, conolidine modulates alternate molecular targets. A Science Advancements review found that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://snoopq008ycg2.nico-wiki.com/user